GlassScriptPhysician profile
Raul Couret
NPI 1306969696
$6,221.37
in general payments reported to CMS, 2019-2025
49 companies · $472 in 2025
The $472 reported for 2025 was more than what 80% of Geriatric Medicine (Family Medicine) providers received nationally (typical 2025 total: $119).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,912 · 2020: $1,360 · 2021: $907 · 2022: $574 · 2023: $543 · 2024: $453 · 2025: $472.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,435 · Education: $32.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,435.21 |
| Education | $32.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $909.36 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $588.09 | 2019-2024 | |
| Abbvie INC. | $528.15 | 2019-2025 | Vraylar, Ubrelvy, Synthroid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $469.51 | 2019-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $391.67 | 2019-2024 | Xarelto |
| Astellas Pharma US INC | $388.86 | 2019-2023 | Veozah, Myrbetriq |
| Astrazeneca Pharmaceuticals LP | $374.79 | 2019-2024 | Farxiga, Movantik |
| Glaxosmithkline, LLC. | $321.98 | 2019-2023 | Shingrix, Arexvy, Trelegy Ellipta |
| Amgen INC. | $233.62 | 2019-2023 | Repatha |
| Sunovion Pharmaceuticals INC. | $186.65 | 2019 | |
| Lilly USA, LLC | $180.49 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $167.48 | 2019-2025 | |
| Avanir Pharmaceuticals, INC. | $129.28 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $120.85 | 2023-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $113.72 | 2019-2021 |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raul Couret listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.